scholarly journals Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial

2021 ◽  
Author(s):  
Johann S de Bono ◽  
Niven Mehra ◽  
Giorgio V Scagliotti ◽  
Elena Castro ◽  
Tanya Dorff ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Dna Repair ◽  
Phase 2 ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Phase 2 Trial ◽  
Castration Resistant ◽  
Open Label Phase

Investigation of metformin (MET) in patients with castration resistant prostate cancer (CRPC) in combination with enzalutamide (ENZ) vs. ENZ alone: A randomized, open label, phase 2 trial. SAKK 08/14—IMPROVE.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS5086-TPS5086
Author(s):  
Christian Alexander Rothermundt ◽  
Richard Cathomas ◽  
Alexandros Xyrafas ◽  
Martina Schneider ◽  
Christine Biaggi Rudolf ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase 2 ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Phase 2 Trial ◽  
Castration Resistant ◽  
Open Label Phase

[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial

The Lancet ◽  
2021 ◽  
Vol 397 (10276) ◽  
pp. 797-804 ◽  
Author(s):  
Michael S Hofman ◽  
Louise Emmett ◽  
Shahneen Sandhu ◽  
Amir Iravani ◽  
Anthony M Joshua ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Phase 2 ◽  
Castration Resistant Prostate Cancer ◽  
Open Label ◽  
Phase 2 Trial ◽  
Castration Resistant ◽  
Open Label Phase
Sign in / Sign up

Export Citation Format

Share Document